Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, entered the next phase in its partnership with FluGen, Inc., a clinical-stage vaccine company. Naobios will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine-candidate for their upcoming clinical trials beginning in 2022 in the U.S.   Naobios and FluGen have been collaborated on the process development ...